- Reaction score
- 42
About a month and a half ago, Guillermo alerted us all to a supposedly "new" dutasteride study that had just appeared in one of the medical journals. As I pointed out at the time, it wasn't actually anything new, just the formal publication of the same clinical trial for hairloss that Glaxo did a few years ago. The essential data from that trial (haircounts, side-effect percentages, etc.) have already been available for a long time and have been widely discussed on these hairloss sites. However, I just obtained the full 10-page study from the medical library this evening, and I've given it a quick read-through. All the haircount data is exactly the same as what we've known for a long time, but there are a couple of other minor surprises which I wasn't expecting:
1) They also performed both serum and scalp before-and-after testosterone and DHT measurements on the various treatment groups (dutasteride, finasteride, and placebo)!
2) The main efficacy end-point was the haircount data, but they also did expert panel and investigator photographic assessment of not only vertex improvement, but also frontal improvement!
I personally have never been particularly interested in measurements of scalp DHT, for reasons which I've already explained until I'm blue in the face. However, I know that many of the rest of you are, so I'll quote a few passages from the text of the study on what their results were, along with their own brief discussion of another earlier study which got very different results. Also, this theory about losing frontal hair on dutasteride has been all the rage lately, so I'll quote what they said about the photographic assessment of the frontal part of the scalp while on dutasteride and finasteride. Here are the two sections, one after another:
So there you have it: despite some pretty wild conspiracy theories floating around here that the researchers noticed frontal thinning during the Glaxo trial and that that's at least one of the reasons why they stopped further male pattern baldness development for dutasteride, that claim isn't supported by this study. Both the expert panel and the investigators reported significantly improved FRONTAL hair in the dutasteride groups than in the finasteride group.
Bryan
1) They also performed both serum and scalp before-and-after testosterone and DHT measurements on the various treatment groups (dutasteride, finasteride, and placebo)!
2) The main efficacy end-point was the haircount data, but they also did expert panel and investigator photographic assessment of not only vertex improvement, but also frontal improvement!
I personally have never been particularly interested in measurements of scalp DHT, for reasons which I've already explained until I'm blue in the face. However, I know that many of the rest of you are, so I'll quote a few passages from the text of the study on what their results were, along with their own brief discussion of another earlier study which got very different results. Also, this theory about losing frontal hair on dutasteride has been all the rage lately, so I'll quote what they said about the photographic assessment of the frontal part of the scalp while on dutasteride and finasteride. Here are the two sections, one after another:
Materials And Methods. Scalp testosterone and DHT concentrations were determined in 4-mm biopsy specimens taken at baseline and again at 24 weeks. The biopsy specimens were taken anterolateral to the leading edge of the vertex bald spot, adjacent to the target area for hair counts. Scalp testosterone and DHT were measured after tissue homogenization and ether extraction, using the same assay as for serum measurements. Results. [...] Scalp DHT concentrations in the dutasteride groups were also significantly suppressed compared with placebo in a dose-related manner. As with serum DHT, the 0.1-mg dutasteride and finasteride groups showed a comparable degree of scalp DHT suppression (32% and 41%, respectively). Scalp DHT decreased by 51% with 0.5-mg dutasteride and by 79% with 2.5-mg dutasteride. Scalp testosterone levels significantly increased in all active treatment groups compared with placebo, increasing by 23%, 39%, 99%, and 222% with 0.5-, 0.1-, 0.5 and 2.5-mg dutasteride, respectively, and 23% with finasteride.
Materials And Methods. [...] For expert panel assessment of global changes in the amount of hair, photographs were taken of both the vertex and frontal scalp. A panel of experts (Drs Olsen, Savin and Whiting), blinded as to treatment, was shown pairs of photographs from baseline and either 12 or 24 weeks of treatment from each view. The panel graded the changes in hair growth on a 7-point rating scale: greatly, moderately, or slightly decreased; no change; slightly, moderately, or greatly increased; ratings were then converted to numbers (-3 to +3) for statistical analysis. [...] Investigator and subject assessments were done at baseline and at 12 and 24 weeks. For the investigator assessments, baseline photographs were provided for comparative purposes and the investigators used the same 7-point rating scale al already described for the expert photographic panel. The subjects were asked to rate changes in the size of the vertex spot, hair loss on top of the scalp, bitemporal recession, the amount of hair shedding, hair quality, and overall satisfaction with hair growth on a 3-point scale (improved, no change, or worse). Results. [...] In the frontal region, the dutasteride 0.1, 0.5, and 2.5 mg groups improved significantly more than placebo at both 12 and 24 weeks. Finasteride was not significantly different from placebo at 12 weeks (P = .69) but was at 24 weeks (P < .001). At 12 weeks, the improvement in the 0.5-mg dutasteride group (0.28 +/- 0.40) and in the 2.5-mg dutasteride group (0.37 +/- 0.46) was significantly greater than the finasteride group (0.09 +/- 0.39, P = .009 and P < .001, respectively). At 24 weeks, the improvement in the 2.5-mg dutasteride group (0.85 +/- 0.79) was also significantly greater than the finasteride group (0.51 +/- 0.66, P = .002). The proportions of patients judged to have improved hair growth (slightly to greatly increased) at 24 weeks in the frontal photographs were 12%, 22%, 33%, 48%, and 61% for placebo, 0.05, 0.1, 0.5 and 2.5 mg dutasteride, respectively, and 45% for finasteride. The proportion of patients with moderate or greater increases was higher with dutasteride 0.5 and 2.5 mg than with finasteride for both vertex and frontal photographs. Investigators' Global Assessment. [...] At the frontal scalp....the 2.5-mg dutasteride group also showed a significant increase compared with finasteride (P < .001) at 12 weeks. At 24 weeks, dutasteride 0.1, 0.5, and 2.5 mg and finasteride groups showed significantly more improvement than the placebo group. The 2.5-mg dutasteride group (1.38 +/- 0.93) was also significantly more improved than finasteride (0.83 +/- 0.95, P < .001).
So there you have it: despite some pretty wild conspiracy theories floating around here that the researchers noticed frontal thinning during the Glaxo trial and that that's at least one of the reasons why they stopped further male pattern baldness development for dutasteride, that claim isn't supported by this study. Both the expert panel and the investigators reported significantly improved FRONTAL hair in the dutasteride groups than in the finasteride group.
Bryan